Associated tags: Neoplasm, Acute myeloid leukemia, Virus, STS, Biotechnology, AML, Pharmaceutical industry, Cancer, Brain, T-cell lymphoma, COVID-19, Antimetabolite, Conference, Patient, Safety
Locations: TEXAS, EUROPE, UNITED STATES, EUROPEAN UNION, US, SLOAN, NEW YORK
HOUSTON, March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.
Key Points:
- Live webcast fireside chat on Monday, March 18th at 9:00 AM PT
HOUSTON, March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.
- In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
- For more information about the event, please visit the conference website .
- A live webcast of the fireside chat will be available on the Events page in the Investors section of the Company's website ( moleculin.com ).
Retrieved on:
Wednesday, January 24, 2024
Northwestern University,
Neutrophil,
Patient,
Research,
OS,
Acute myeloid leukemia,
Anthracycline,
Culture,
Survival,
Mouse,
CRS,
Thrombocytopenia,
Safety,
Allergy,
STS,
GBM,
PFS,
Febrile neutropenia,
Bone marrow,
Cardiotoxicity,
NIH,
Glioblastoma,
Brain,
Zika virus,
FDA,
Virus,
HIV,
Aplastic anemia,
National Institutes of Health,
AML,
Clinical trial,
Bangladesh Technical Education Board,
SARS-CoV-2,
Pharmacokinetics,
ITT,
Pharmaceutical industry "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.
Key Points:
- "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.
- We are well-positioned to continue building upon our encouraging growing body of preliminary clinical data and transition to pivotal Phase 2B/3 clinical trials by year-end 2024.
- With our recent financing in December 2023, we have extended our runway into the fourth quarter of 2024, as well.
- WP1122 successfully completed a Phase 1 clinical trial, which established a recommended safe dose for future potential Phase 1B or Phase 2 clinical trials.
Retrieved on:
Monday, November 13, 2023
Webcast,
Research,
Safety,
Clinical trial,
STS,
Patient,
ANN,
Conference,
Cardiotoxicity,
Private law,
Virus,
Metastasis,
Virtual,
R,
AML,
Pharmaceutical industry,
Cryptocurrency HOUSTON, Nov. 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended September 30, 2023. As previously announced, the Company will host a conference call and live audio webcast, today, November 13, 2023, at 8:30 AM ET (details below).
Key Points:
- HOUSTON, Nov. 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended September 30, 2023.
- As previously announced, the Company will host a conference call and live audio webcast, today, November 13, 2023, at 8:30 AM ET (details below).
- General and administrative expense was $2.6 million and $3.1 million for the three months ended September 30, 2023 and 2022, respectively.
- Moleculin management will host its quarterly conference call and webcast for investors, analysts, and other interested parties today, November 13, 2023, at 8:30 AM ET.
Retrieved on:
Tuesday, November 7, 2023
HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday November 13, 2023.
Key Points:
- HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday November 13, 2023.
- Moleculin management will host a conference call and live webcast to discuss the operational and financial results at 8:30 AM ET that same day.
- Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call.
- The live webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com , and will be archived for 90 days.
Șaeș,
ECHO,
Acute myeloid leukemia,
Physical examination,
Aes,
Food,
Progression-free survival,
ECOG,
Wireless ambulatory ECG,
Treatment,
MD,
Eastern Cooperative Oncology Group,
PFS,
Doctor of Philosophy,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Virus,
HIV disease progression rates,
SD,
Washington University School of Medicine,
Clinical trial,
Cardiotoxicity,
STS,
RECIST,
ANN,
Safety,
Vital signs,
Patient,
Toxicity,
Pharmaceutical industry HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company's ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
Key Points:
- Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
- We look forward to further data readouts from this trial and understanding the full potential of Annamycin for the treatment of STS lung mets."
- The other subject maintained SD through 8 cycles prior to progressing ~6.9 months after initiating treatment with Annamycin.
- Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.
Retrieved on:
Wednesday, October 11, 2023
HOUSTON, Oct. 11, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard to treat tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer and Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin, will participate at the Virtual Investor Ask the CEO Conference on Tuesday, October 25, 2023 at 12:00 PM ET
Key Points:
- Investors and interested parties will have the opportunity to submit questions live during the event.
- Participating companies will answer as many questions as possible during the event.
- A live video webcast of the event will be available on the Events page of the Investors section of the Company's website ( moleculin.com ).
- A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
US Foods,
STS,
AML,
Doxorubicin,
CRi,
Lung,
Anthracycline,
FDA,
Virus,
Food,
Safety,
Pharmaceutical industry,
Cytarabine HOUSTON, Oct. 2, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today announced the initial subjects have been treated in the Phase 2 portion of the Company's Phase 1B/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) for the treatment of subjects with AML (MB-106).
Key Points:
- Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "This milestone marks an important step in advancing the development of Annamycin for the treatment of AML.
- Based on the positive preliminary results demonstrated in the Phase 1B portion of this trial, we continue to believe that Annamycin has the potential to be a meaningful treatment option for the treatment of AML.
- As previously announced, Moleculin successfully and safely completed the Phase 1B portion of the trial at 230 mg/m2 of Annamycin in this combination study in August 2023.
- For more information about the MB-106 Phase 1/2 trial, visit clinicaltrialsregister.eu and reference EudraCT 2020-005493-10 or clinicaltrials.gov and reference NCT05319587.
Retrieved on:
Thursday, September 21, 2023
Progression-free survival,
Aes,
Clinical trial,
ECHO,
STS,
Toxicity,
PFS,
Physical examination,
Acute myeloid leukemia,
Eastern Cooperative Oncology Group,
Vital signs,
HIV disease progression rates,
Patient,
ECOG,
Annual general meeting,
Wireless ambulatory ECG,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Virus,
Treatment,
Food,
Safety,
Pharmaceutical industry HOUSTON, Sept. 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today announced the completion of enrollment in the Phase 2 portion of the Company's U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107). Subjects who had stable disease at time of study discontinuation will continue to be followed for progression free response and overall survival.
Key Points:
- Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
- Subjects who had stable disease at time of study discontinuation will continue to be followed for progression free response and overall survival.
- "The completion of enrollment for our MB107 study marks an important milestone for our STS clinical development program.
- Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.
Retrieved on:
Thursday, September 14, 2023
HOUSTON, Sept. 14, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023 in Dublin, Ireland.
Key Points:
- HOUSTON, Sept. 14, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023 in Dublin, Ireland.
- Details of the presentation are as follows:
For more information about the CTOS, please visit the conference website, here .
Retrieved on:
Tuesday, September 5, 2023
HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.
Key Points:
- HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.
- In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
- For more information about the conference, please visit the conference website .
- The webcast replay will be archived for 90 days following the event.
